FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to incl...( The U.S. Food and Drug Administratio...),Health
Navigation Links
FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
Date:9/19/2007
The U.S. Food and Drug Administration (FDA) has approved the expanded use of FluMist (influenza virus vaccine live, intranasal) in children two to five years of age. FluMist is now approved for active immunization for the prevention of disease caused by influenza A and B viruses in individuals two to 49 years of age.1 Only one manufacturer had previously been licensed in the United States to produce influenza vaccine for children under four years of age.
In a pivotal study that included more than 4,000 children between the ages of two and five years of age during the 2004-2005 influenza season, there was a 54 percent reduction in cases of flu in children who received FluMist compared with those who received the traditional flu shot (4.5 percent vs. 9.8 percent, respectively).2 In the study, FluMist demonstrated a reduction in influenza rates compared to the inactivated vaccine against strains that were both matched and mismatched to the vaccine. FluMist is different from the flu shot in that it uses live, attenuated or weakened viruses within the vaccine to help stimulate an immune response that is designed to closely resemble the bodys natural response to an infection.3
FluMist will be available for the 2007-2008 influenza season. For more information about FluMist visit www.FluMist.com or call 1-877-FLUMIST (1-877-358-6478).
'/>"/>
| Contact: Maria Dottori dottorim@fleishman.com 212-453-2429 Fleishman-Hillard, Inc. Source:Eurekalert |
Related medicine news :
1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. FDA Approves Contraceptive Ring
3. FDA approves new device to treat womens bleeding disorder
4. FDA Approves New HIV Drug, Viread
5. FDA Approves Birth Control Skin Patch
6. FDA approves surgical gel
7. FDA Approves New Arthritis Drug, Bextra
8. FDA Approves Elidel Cream for Eczema
9. FDA approves drug for rare liver disease
10. FDA approves first pocket-sized EKG machine
11. FDA Approves New Anti-Clotting Drug
Post Your Comments:
(Date:11/30/2009)...SCHAFFHAUSEN, Switzerland, Nov. 30 /PRNewswire-Fir...today announced that its 2010 annual general meeti...h 10, 2010 at 3:00 p.m. Central European time at t...8002 Zurich, Switzerland. Registered shareholders ...ntitled to vote at the annual general meeting. Ad...
(Date:11/30/2009)... tiny period of time between the registration of a...onscious recognition of it ― between the tim...an apple. Our minds lag behind our eyes, but by ho...the world around us? , Some estimates say the ... 500 milliseconds. A new study by Tel Aviv Univers...
(Date:11/30/2009)...ies report safe transplant results in animals , ...o new studies in animals suggest that stem cells f...d could help treat some lung and heart disorders. ... can differentiate into a long list of different k... of the Samsung Medical Center in Seoul, Korea, co...
(Date:11/30/2009)...HORT HILLS, N.J., Nov. 30 Kemin Fo...gies, Inc. and OmniActive Health Technologies, Ltd...nt of their dispute. The parties agree that Kemin,...ed "Process for Isolation, Purification and Recrys...oresin and Uses Thereof" and the reissues of that ...
(Date:11/30/2009)... , NASHVILLE, Tenn., Nov. 30 Du...t gifts for the holidays. For a loved one with Alz... members and friends oftentimes struggle with appr... , one of the leading providers of senior living r...d dementia care , offers these suggestions. ,, ...
Breaking Medicine News(10 mins):Health News:Now you see it, now you know you see it 2Health News:Gift Ideas for Loved Ones with Alzheimer's/Dementia 2[1] Tyco International Sets Date for 2010 Annual General Meeting of Shareholders[0] Now you see it, now you know you see it[0] Cord Blood Stem Cells May Help Treat Heart, Lung Disorders[0] OmniActive and Kemin Reach Amicable Settlement in Patent Dispute[0] Gift Ideas for Loved Ones with Alzheimer's/Dementia
...PLEASANTON, Calif., FRAMINGHAM, Mass., SYDNEY, Feb...on (Nasdaq: THOR ), a world leader in device-,ba...ve, support and restore,failing hearts, and HeartW...nitive merger agreement under which Thoratec will,...
...ical collaboration and integration of electronic m...out NE Ohio , , CLEVELAND, Feb. 13 Cleveland Cli... MinuteClinic, the pioneer and largest provider of...enient, seven-day-a-week option for those with acu...
... Mr Keith Borowsky, an eminent... Medical School has chosen a Mecmesin MultiTest 10...uct research on a new orthopaedic prosthesis for s...n at the University of Brighton Medical School has...
...laint filed in Superior Court for the Commonwealth...ire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ; TSX: Q...al Hospital Corporation, doing business as Massach...Inc. QLT Phototherapeutics (Canada), Inc. was a pr...
...d gender also affect chances of having debilitatin...ay News) -- Being overweight may increase the risk...ults, suggests a U.S. study that included 22,211 p...have migraines than those with smaller waistlines....
... The non-profit Hospice By The...ve care, is offering specialized trainings in end-...sionals in Marin, San Francisco, and Sonoma counti...ngs, which are repeated monthly, contact Hospice,s...
Other Medicine News:Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 2Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 3Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 4Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 5Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 6Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 7Health News:Cleveland Clinic Enters into Agreement with MinuteClinic 2Health News:Cleveland Clinic Enters into Agreement with MinuteClinic 3Health News:Cleveland Clinic Enters into Agreement with MinuteClinic 4Health News:Force Tester Shoulders The Burden 2Health News:QLT announces that it is named as a defendant in an action 2Health News:QLT announces that it is named as a defendant in an action 3Health News:Belly Fat May Make Migraines More Likely 2Health News:Hospice By The Bay Offers Health Care Professionals Free Training in End-of-Life Care 2Health News:Hospice By The Bay Offers Health Care Professionals Free Training in End-of-Life Care 3Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;Cleveland Clinic Enters into Agreement with MinuteClinicForce Tester Shoulders The BurdenQLT announces that it is named as a defendant in an actionBelly Fat May Make Migraines More LikelyHospice By The Bay Offers Health Care Professionals Free Training in End-of-Life Care
(Date:11/30/2009)... , NEW YORK, Nov. 30 Repo...report is available in its catalogue: ,, Infla...nce the Immune Response ,, http://www.reportl...s-That-Suppress-or-Balance-the-Immune-Response.htm...er attacking an individual body or producing an ex...
(Date:11/30/2009)... , WALTHAM, Mass., Nov. 30 /PRNewswire/ -...e global authority on medical technology market in...injectable market declined by almost 5% over 2008 ...a result of the economic crisis. The market will, ... return to the strong pre-recession growth rates o...
(Date:11/30/2009)... , WAYNE, N.J. and CHICAGO, Nov. 30 /PRNewswire...ual Meeting of the Radiological Society of North...Inc. announced the enrollment of the first patient...valuate the efficacy and safety of florbetaben (BA...yloid plaques in the brain, which are a pathologic...
Breaking Medicine Technology:Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 2Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 3Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 4Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 5Facial Injectables Emerge From the Recession 2Facial Injectables Emerge From the Recession 3Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease 2Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease 3Internet May Be Newest Venue for Teen Tobacco Exposure 52122 1Internet May Be Newest Venue for Teen Tobacco Exposure 52122 2Internet May Be Newest Venue for Teen Tobacco Exposure 52122 3Feel Fun Fit 26 Fabulous 21 At the 2009 Womens Health Conference 52117 1Feel Fun Fit 26 Fabulous 21 At the 2009 Womens Health Conference 52117 2Feel Fun Fit 26 Fabulous 21 At the 2009 Womens Health Conference 52117 3Our brain looks at eyes first to identify a face 9280 1Our brain looks at eyes first to identify a face 9280 2Our brain looks at eyes first to identify a face 9280 3[0] Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response[0] Facial Injectables Emerge From the Recession[0] Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease
...YVILLE, Calif., Dec. 17 Neurobiological,Technolog...ed that an independent,Data Safety Monitoring Boar...trials of Viprinex(TM) for the treatment of acute ... result, the company has terminated further enroll...e data before evaluating the,potential for any fut...
...YORK, LONDON and HAMILTON, Bermuda, Dec. 16 Celt...announced today that the databases have been locke...uble-blinded studies of XERECEPT (R) (corticoreli...dema, as well as an initial database lock on the o... efficacy. , , The results of these studies a...
Other Medicine Technology:Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis 2Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |